Spontaneous pyogenic vertebral osteomyelitis in nondrug users

Nolla, Joan M.; Ariza, Javier; Gómez-Vaquero, Carmen; Fiter, J; Bermejo, Josep Oriol; Valverde, J; Escofet, Daniel Roig; Gudiol, Francesc

doi:10.1053/sarh.2002.29492

Cited by 239 publications

(170 citation statements)

References 25 publications

Supporting

Mentioning

117

Contrasting

Unclassified

Order By: Relevance

“…as is the case with fluoroquinolones, clindamycin, or linezolid. Linezolid is mainly used in cases of MRSA infection, although one should be aware of the haematopoietic side effects [6,18,19].…”

Section: General Management Of Spondylodiscitismentioning

confidence: 99%

See 1 more Smart Citation

Treatment of spondylodiscitis

Zarghooni

Röllinghoff

Sobottke

et al. 2011

International Orthopaedics (SICOT)

175

139

View full text Add to dashboard Cite

Purpose Pyogenic infections of the spine are relatively rare with an incidence between 1:100,000 and 1:250,000 per year, but the incidence is increasing due to increases in average lifeexpectancy, risk factors, and medical comorbidities. The mean time in hospital varies from 30 to 57 days and the hospital mortality is reported to be 2-17%. This article presents the relevant literature and our experience of conservative and surgical treatment of pyogenic spondylodiscitis. Method We have performed a review of the relevant literature and report the results of our own research in the diagnosis and treatment of pyogenic spondylodiscitis. We present a sequential algorithm for identification of the pathogen with blood cultures, CT-guided biopsies and intraoperative tissue samples. Basic treatment principles and indications for surgery and our surgical strategies are discussed. Results Recent efforts have been directed toward early mobilisation of patients using primary stable surgical techniques that lead to a further reduction of the mortality. Currently our hospital mortality in patients with spondylodiscitis is around 2%. With modern surgical and antibiotic treatment, a relapse of spondylodiscitis is unlikely to occur. In literature the relapse rate of 0-7% has been recorded.

show abstract

Section: General Management Of Spondylodiscitismentioning

confidence: 99%

“…In the literature, the average duration between the first symptoms and diagnosis has been reported to be between two and six months [1][2][3][4][5][6][7][8].…”

Section: Introductionmentioning

confidence: 99%

Treatment of spondylodiscitis

Zarghooni

Röllinghoff

Sobottke

et al. 2011

International Orthopaedics (SICOT)

175

139

View full text Add to dashboard Cite

show abstract

“…In the past, coagulase-negative staphylococci rarely caused infections of clinical relevance, but the continued use of cardiac and joint catheters and prostheses has led to an increase in its pathogenic capacity, especially in immunocompromised patients. Currently, coagulase-negative staphylococci are responsible for about 3-18% of infectious spondylodiscitis cases; [8][9][10][11][12] this percentage increases to 25-30% in post-surgery cases. 13,14 The most common coagulase-negative subspecies is St. epidermidis (72%) followed by St. lugdunensis (7%).…”

Section: Discussionmentioning

confidence: 99%

Espondilodiscite atípica

et al. 2013

View full text Add to dashboard Cite

Infections with coagulase-negative Staphylococcus correspond to a small percentage of the total pyogenic spondylodiscitis and are associated with immunocompromised conditions. We present a case of a 58 year old male with a L1-L2 spondylodiscitis by a very atypical microorganism, the S. hominis. Only after two surgeries and specific antibiotic therapy it was possible to eliminate the disease.Keywords: Staphylococcus, Staphylococcus hominis; Discitis. RESUMO

show abstract

“…2,5,13,22,34,35,36 Multi-level localisation of SS in most studies ranges between 3% and 13%. 2,12,13,17,18,27,37,38 The greatest frequency of multi-segment involvement -68%, is reported in the study of Patzakis MJ et al, involving large numbers of patients on continuous intravenous therapy. 39 The period between the debut of disease to diagnosis varies between 1 and 6 months.…”

Section: Clinical Presentationmentioning

confidence: 97%

“…In SS it is elevated like ESR. 2,5,37,39 CRP normalizes faster than ESR and is an useful indicator of an improvement. 4 CRP levels drop by 50% per week is a good predictor for the treatment of the disease.…”

Section: Laboratory Testsmentioning

confidence: 99%

Spontaneous Spondylodiscitis - Epidemiology, Clinical Features, Diagnosis and Treatment

2017

View full text Add to dashboard Cite

Spontaneous spondylodiscitis is a rare but serious infectious disease which is a combination of an inflammatory process, involving one or more adjacent vertebral bodies (spondylitis), the intervertebral discs (discitis) and finally - the neighboring neural structures. In most cases the condition is due to a hematogenous infection and can affect all regions of the spinal cord, but it is usually localized in the lumbar area. The most common clinical symptom is a pronounced, constant and increasing nocturnal paravertebral pain, while consequently different degrees of residual neurological symptoms from nerve roots and/or spinal cord may appear. The disease course is chronic and the lack of specific symptoms often prolongs the time between its debut and the diagnosis. This delay in diagnosis determines its potentially high morbidity and mortality. Treatment is conservative in cases with no residual neurological symptoms and consists of antibiotic therapy and immobilization. Surgical treatment is necessary in patients with neurological deficit, spinal instability or drug resistance.

show abstract

Spontaneous pyogenic vertebral osteomyelitis in nondrug users

Cited by 239 publications

References 25 publications

Treatment of spondylodiscitis

Treatment of spondylodiscitis

Espondilodiscite atípica

Spontaneous Spondylodiscitis - Epidemiology, Clinical Features, Diagnosis and Treatment

Contact Info

Product

Resources

About